uploads///Chart

Allergan’s Business Segments in 1Q18

By

Nov. 20 2020, Updated 4:25 p.m. ET

Allergan’s business segments

As we discussed earlier, Allergan (AGN) has restructured its business over the last few years, and its business is classified into three segments:

  • US Specialized Therapeutics
  • US General Medicine
  • International

The chart below compares the segment-wise revenues for Allergan since 1Q17.

Article continues below advertisement

US Specialized Therapeutics segment

Allergan’s US Specialized Therapeutics segment includes its revenues from the US sales of products related to eye care, medical aesthetics, medical dermatology, neuroscience, and urology. Allergan’s US Specialized Therapeutics business revenues rose 6.5% to $1.6 billion during 1Q18, compared to $1.5 billion during 1Q17. This growth was driven by new acquisitions and increased sales of key brands.

US General Medicine segment

The US General Medicine business includes revenues from the sales of general products related to the central nervous system, women’s health, and gastroenterology, as well as anti-infectives and diversified brands.

The US General Medicine segment’s revenues fell 9.1% to $1.2 billion during 1Q18, compared to $1.3 billion during 1Q17. This decrease was driven by lower sales of central nervous system products, women’s health products, and products from its diversified brands portfolio.

International segment

Allergan’s International business includes the revenues from sales outside the US markets. These revenues include Botox therapeutics products, eye care products, medical aesthetics products, and other products.

Revenues from the company’s International segment rose 17.2% to $864.0 million during 1Q18, compared to $737.0 million during 1Q17. This includes 9.0% growth in revenues at constant exchange rates and an 8.2% positive impact of foreign exchange during 1Q18.

The SPDR S&P Pharmaceuticals ETF (XPH) holds 4.3% of its portfolio in Allergan (AGN), 4.3% in Pfizer (PFE), 4.5% in Eli Lilly (LLY), and 4.2% in Johnson & Johnson (JNJ).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Advertisement

More From Market Realist

  • Honeywell sign
    Earnings Report
    CNBC Pro Stocks to Buy Before Q1 Earnings
  • Men walking by Morgan Stanley headquarters
    Financials
    Morgan Stanley’s (MS) Stock Forecast Before Q1 Earnings
  • Carnival cruise ship sailing
    Consumer
    Carnival's (CCL) Stock Forecast Before Q1 Business Update
  • GameStop store
    Consumer
    GME's Earnings Are Coming: Will It Be Mayday for Shorts or WallStreetBets?
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.